Treatment of newly diagnosed multiple myeloma in transplant-eligible patients

Recent advances in novel therapeutic agents, such as proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies, have markedly improved treatment outcomes in patients with multiple myeloma. The novel agent-based induction, followed by autologous transplantation, is considered as the standard treatment for transplant-eligible patients. Post-transplant consolidation and maintenance therapy can help maintain the subsequent response and further improve the treatment outcome in patients. Currently, there are several validated sensitive assays evaluating minimal residual disease (MRD), which have provided a means to quantitatively assess residual disease and accurately predict its prognosis in terms of progression-free and overall survival. Novel clinical studies that formally assess the effect of MRD negativity on clinical decision-making are ongoing. This session aims to provide an in-depth and comprehensive summary of the latest treatment strategy and MRD-based knowledge in newly diagnosed transplant-eligible patients with multiple myeloma.

Medienart:

E-Artikel

Erscheinungsjahr:

2020

Erschienen:

2020

Enthalten in:

Zur Gesamtaufnahme - volume:61

Enthalten in:

Rinsho ketsueki] The Japanese journal of clinical hematology - 61(2020), 9 vom: 25., Seite 1306-1316

Sprache:

Japanisch

Beteiligte Personen:

Sakaida, Emiko [VerfasserIn]

Links:

Volltext

Themen:

Antibodies, Monoclonal
High dose melphalan
Journal Article
MRD
Maintenance treatment
Proteasome Inhibitors
Transplant-eligible myeloma

Anmerkungen:

Date Completed 18.01.2021

Date Revised 18.01.2021

published: Print

Citation Status MEDLINE

doi:

10.11406/rinketsu.61.1306

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM317303031